Fresenius Kabi Oncology Ltd, Board Meeting, Apr 17, 2013. Agenda: To take on record the Delisting Offer proposed to be made by Fresenius Kabi (Singapore) Pte Ltd; to approve launch and implementation of the Delisting Offer, subject to the approval of the shareholders of the company and other regulatory approvals, consents, permissions and / or sanctions that may be required and subject to such conditions; and to seek the approval of the shareholders of the company for the Delisting Offer by way of a special resolution through postal ballot in accordance with the provisions of Section 192A of the Companies Act, 1956 read with the Companies.

Fresenius Kabi Oncology Ltd. announced that during a recent routine US FDA inspection at company's API plant located at Kalyani, District Nadia, West Bengal, (India), US FDA made certain observations relating to GMP non-conformities in respect of manufacturing, documentation practices and product testing. However, all finished products conform to approved standards and specifications. The company has immediately taken steps to implement remedial measures and has voluntarily put the production on hold. The company's dosage form plants in Himachal Pradesh continue normal production.

Fresenius Kabi Oncology Ltd. informed that the Board of Directors of the company at its meeting held on February 13, 2013, approved the appointment of Dr. Patricia Grigoleit as an additional director of the company with effect from February 13, 2013. The meeting also approved the appointment of Dr. Satish B. Kulkarni as an Alternate Director in place of Mr. Thomas George Mechtersheimer. This appointment was effective for the Board Meeting dated February 13, 2013 and Dr. Kulkarni resigned from the Alternate Directorship at the conclusion of the meeting.